Corrigendum (Clinical Genitourinary Cancer (2020) 18(1) (69–76.e4), (S1558767319302794), (10.1016/j.clgc.2019.09.010))

Orazio Caffo, Michel Wissing, Ugo De Giorgi, Stéphane Oudard

Research output: Contribution to journalComment/debatepeer-review

Abstract

Corrigendum to “Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer” [Clinical Genitourinary Cancer. 2020 Feb;18(1):69-76.e4] Orazio Caffo, 1 Michel Wissing, 2 Diletta Bianchini, 3 Andries Bergman, 4 Frederik B. Thomsen, 5 Sebastian Schmid, 6 Evan Y. Yu, 7 Evangelos Bournakis, 8 Avishay Sella, 9 Vittorina Zagonel, 10 Ugo De Giorgi, 11 Marcello Tucci, 12 Hans Gelderblom, 2 Luca Galli, 13 Giovanni Pappagallo, 14 Emilio Bria, 15 Isabella Sperduti, 16 Stephane Oudard, 17 on behalf of the CASTOR study investigators 1Medical Oncology Department, Santa Chiara Hospital, Trento, Italy 2Medical Oncology Department, University Medical Centre, Leiden, the Netherlands 3Division of Clinical Studies, Prostate Cancer Targeted Therapies Group, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom 4Division of Internal Medicine (MOD) and Oncogenomics, Netherlands Cancer Institute, Amsterdam, the Netherlands 5Copenhagen Prostate Cancer Center, Rigshospitalet, Copenhagen, Denmark 6Klinik und Poliklinik für Urologie, Klinikum rechts der Isar der Technischen Universität München, München, Germany 7Department of Medicine, University of Washington School of Medicine, Seattle, WA 8Oncology Department, ARETAIEIO University Hospital of Athens, IASO General Clinic of Athens, Athens, Greece 9Department of Oncology, Yitzhak Shamir Medical Center, Assaf Harofe Campus Harofeh Medical Center, Sackler School of Medicine, Tel-Aviv, Israel 10Medical Oncology Department, Istituto Oncologico Veneto, Padua, Italy 11Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy 12Medical Oncology Department, Azienda Ospedaliera Universitaria S. Luigi Gonzaga, Orbassano, Italy 13Medical Oncology Department, Azienda Ospedaliera Universitaria, Pisa, Italy 14Epidemiology & Clinical Trials Office, General Hospital, Mirano, Italy 15Oncology Unit, Università Cattolica del Sacro Cuore, Fondazione Policlinico “A. Gemelli”, Rome, Italy 16Biostatistical Unit, Regina Elena National Cancer Institute, Rome, Italy 17Service de cancérologie médicale, Hôpital Européen Georges Pompidou, René Descartes University, Paris, France The authors regret that the affiliation information for Vittorina Zagonel, Ugo De Giorgi, and Isabella Sperduti was incorrect in their published article. The correct details are given below. Orazio Caffo, 1 Michel Wissing, 2 Diletta Bianchini, 3 Andries Bergman, 4 Frederik B. Thomsen, 5 Sebastian Schmid, 6 Evan Y. Yu, 7 Evangelos Bournakis, 8 Avishay Sella, 9 Vittorina Zagonel, 10 Ugo De Giorgi, 11 Marcello Tucci, 12 Hans Gelderblom, 2 Luca Galli, 13 Giovanni Pappagallo, 14 Emilio Bria, 15 Isabella Sperduti, 16 Stephane Oudard, 17 on behalf of the CASTOR study investigators 1Medical Oncology Department, Santa Chiara Hospital, Trento, Italy 2Medical Oncology Department, University Medical Centre, Leiden, the Netherlands 3Division of Clinical Studies, Prostate Cancer Targeted Therapies Group, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom 4Division of Internal Medicine (MOD) and Oncogenomics, Netherlands Cancer Institute, Amsterdam, the Netherlands 5Copenhagen Prostate Cancer Center, Rigshospitalet, Copenhagen, Denmark 6Klinik und Poliklinik für Urologie, Klinikum rechts der Isar der Technischen Universität München, München, Germany 7Department of Medicine, University of Washington School of Medicine, Seattle, WA 8Oncology Department, ARETAIEIO University Hospital of Athens, IASO General Clinic of Athens, Athens, Greece 9Department of Oncology, Yitzhak Shamir Medical Center, Assaf Harofe Campus Harofeh Medical Center, Sackler School of Medicine, Tel-Aviv, Israel 10Medical Oncology Department, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy 11Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy 12Medical Oncology Department, Azienda Ospedaliera Universitaria S. Luigi Gonzaga, Orbassano, Italy 13Medical Oncology Department, Azienda Ospedaliera Universitaria, Pisa, Italy 14Epidemiology & Clinical Trials Office, General Hospital, Mirano, Italy 15Oncology Unit, Università Cattolica del Sacro Cuore, Fondazione Policlinico “A. Gemelli”, Rome, Italy 16Biostatistical Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy 17Service de cancérologie médicale, Hôpital Européen Georges Pompidou, René Descartes University, Paris, France The authors would like to apologise for any inconvenience caused. Address for correspondence: Orazio Caffo, MD, Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d'Oro, 38122 Trento, Italy E-mail contact: orazio.caffo@apss.tn.it

Original languageEnglish
Pages (from-to)e416-e417
JournalClinical Genitourinary Cancer
Volume18
Issue number4
DOIs
Publication statusPublished - Aug 2020

Fingerprint

Dive into the research topics of 'Corrigendum (Clinical Genitourinary Cancer (2020) 18(1) (69–76.e4), (S1558767319302794), (10.1016/j.clgc.2019.09.010))'. Together they form a unique fingerprint.

Cite this